Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated No phase listed Observational

Global Non-interventional Heart Failure Disease Registry

ClinicalTrials.gov ID: NCT02595814

Public ClinicalTrials.gov record NCT02595814. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 5:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.

Study identification

NCT ID
NCT02595814
Recruitment status
Terminated
Study type
Observational
Phase
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
18,805 participants

Conditions and interventions

Interventions

Not listed

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 22, 2014
Primary completion
Mar 30, 2018
Completion
Mar 30, 2018
Last update posted
Nov 13, 2018

2014 – 2018

United States locations

U.S. sites
15
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Novartis Investigative Site San Diego California 92103
Novartis Investigative Site San Francisco California 94143-0780
Novartis Investigative Site Chicago Illinois 60611
Novartis Investigative Site Indianapolis Indiana 46202
Novartis Investigative Site Kansas City Kansas 66160
Novartis Investigative Site New Orleans Louisiana 70112
Novartis Investigative Site New Orleans Louisiana 70121
Novartis Investigative Site Detroit Michigan 48201
Novartis Investigative Site Detroit Michigan 48202
Novartis Investigative Site Jackson Mississippi 39216
Novartis Investigative Site New York New York 10029
Novartis Investigative Site Stony Brook New York 11794
Novartis Investigative Site Cincinnati Ohio 45267
Novartis Investigative Site Nashville Tennessee 37203
Novartis Investigative Site Dallas Texas 75390

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 331 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02595814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 13, 2018 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02595814 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →